New pill takes on tough lymphoma: early trial seeks tumor shrinkage

NCT ID NCT06733441

Recruiting now Disease control Sponsor: Treeline Biosciences, Inc. Source: ClinicalTrials.gov ↗

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 2 times

Summary

This early-phase trial tests an oral drug called TLN-254 in about 50 adults with relapsed or refractory T-cell lymphoma. The main goal is to see if the drug can shrink tumors and how safe it is. Participants take the drug by mouth on a set schedule, and researchers will monitor responses and side effects.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: TLN-254 (an oral drug)
What this could lead to: If it works, this could point toward a new treatment option for people with T-cell lymphoma that has not responded to other therapies.
What could go wrong: This is an early Phase 1b trial with only 50 participants, so results are preliminary. The drug may not shrink tumors or could cause side effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for LYMPHOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

lymphoma mature T-cell and NK-cell non-Hodgkin lymphoma mycosis fungoides primary cutaneous T-cell non-Hodgkin lymphoma Recurrence Sezary syndrome

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

LYMPHOMA

Contacts and locations

Locations

British Columbia Cancer Agency
RECRUITING

Vancouver, British Columbia, Canada
Memorial Sloan Kettering Cancer Center
RECRUITING

New York, New York, 10065, United States
Sarah Cannon Research Institute
RECRUITING

Nashville, Tennessee, 37203, United States
Stanford Cancer Institute
RECRUITING

Stanford, California, 94305, United States
Washington University School of Medicine
RECRUITING

St Louis, Missouri, 63110, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.